




# Figures to know about the 2023 Lung Cancer French database



## Selection criteria

**Selection period:** 2015-2022

**Database extracted** in 2023

*Data collected from patient medical files*

*Quality control processes and yearly updates*

- Female or male patients
- $\geq 18$  years old
- who received a first treatment (systemic or radiotherapy) for lung cancer or diagnosed with metastatic lung cancer at one of the 38 participating French medical centers

**51 067** patients in the database

## Median follow-up

*Calculated from advanced or metastatic NSCLC diagnosis, according to reverse Kaplan-Meier method*


**57.3** months

## Minimum estimated follow-up


24 months for **39 991** pts

36 months for **33 761** pts

♂ **33 635** ♀ **17 432**



Median age at  
**initial diagnosis**  
**65** years



**45 809** patients with  
**advanced or metastatic** lung cancer

**5 677** patients with **SCLC**

**41 709** patients with **NSCLC**

**38 062**

patients with **advanced or metastatic NSCLC**


**31 373**

patients with advanced or metastatic NSCLC who received a **first line of treatment**

**8 541**

patients with **unresectable stage III NSCLC**

**14 640** patients with **oncogenic drivers**



**PD-L1** screening performed in **23 594** pts

**TPS  $\geq 1\%$**  in **14 092** patients

**TPS  $\geq 50\%$**  in **6 679** patients